Optimizing Ocular Vestibular Evoked Myogenic Potentials With Narrow Band CE-Chirps.


Journal

Ear and hearing
ISSN: 1538-4667
Titre abrégé: Ear Hear
Pays: United States
ID NLM: 8005585

Informations de publication

Date de publication:
Historique:
pubmed: 19 3 2021
medline: 21 10 2021
entrez: 18 3 2021
Statut: ppublish

Résumé

To evaluate the effects of narrow band CE-Chirp (NB CE-Chirp) on the amplitudes and latencies in ocular vestibular evoked myogenic potentials (oVEMPs) at 500 and 1000 Hz in comparison with tone burst (TB). Twenty-one healthy volunteers were included in the study and tested in air conduction with a "belly-tendon" montage. Recording conditions were randomized for each participant and each modality was tested twice to check the reproducibility of the procedure. NB CE-Chirps at 500 Hz revealed larger n1-p1 amplitudes than 500 Hz TBs (p = .001), which were also larger than NB CE-Chirps and TBs at 1000 Hz (p = .022, p < .001, respectively). Besides, n1 and p1 latencies were shorter in NB CE-Chirp than in TB at 500 Hz (p < .001) and 1000 Hz (p < .001). The older the participants, the lower the amplitudes (p = .021, p = .031) and the longer the n1 (p = .030, p = .025) and p1 latencies (p < .001, p < .001) in 500 Hz NB CE-Chirps and 500 Hz TBs. Interaural asymmetry ratios were slightly higher in 500 Hz NB CE-Chirps as compared to 500 Hz TBs (p = .013). NB CE-Chirps at 500 Hz improved the amplitudes of waveforms in oVEMPs. As for TBs with clicks before, enhancing oVEMPs amplitudes is an essential step to distinguish a healthy person from a patient with either utricular or its related pathways disorder and potentially minimize the risk of cochlear damages. Additional studies including a higher number of healthy participants and patients with vestibular disorders are required to confirm this hypothesis. The large interindividual variability of interaural asymmetry ratios in NB CE-Chirp and in TB at 500 Hz could be explained by the selected montage.

Identifiants

pubmed: 33734171
doi: 10.1097/AUD.0000000000001031
pii: 00003446-900000000-98534
pmc: PMC8378546
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1373-1380

Informations de copyright

Copyright © 2021 The Authors. Ear & Hearing is published on behalf of the American Auditory Society, by Wolters Kluwer Health, Inc.

Déclaration de conflit d'intérêts

The authors have no conflicts of interest to disclose.

Références

J Neurol Neurosurg Psychiatry. 1994 Feb;57(2):190-7
pubmed: 8126503
Clin Neurophysiol. 2007 Feb;118(2):381-90
pubmed: 17141563
Clin Neurophysiol. 2005 Aug;116(8):1938-48
pubmed: 15979939
J Int Adv Otol. 2015 Apr;11(1):33-5
pubmed: 26223715
Acta Otolaryngol. 2012 Dec;132(12):1295-300
pubmed: 23039710
Eur Arch Otorhinolaryngol. 2016 Oct;273(10):2983-91
pubmed: 26758292
Neurology. 2017 Nov 28;89(22):2288-2296
pubmed: 29093067
Am J Audiol. 2017 Jun 13;26(2):180-188
pubmed: 28520834
Clin Neurophysiol. 2007 Dec;118(12):2745-51
pubmed: 17905655
Acta Otolaryngol. 2001 Dec;121(8):935-8
pubmed: 11813898
Eur Arch Otorhinolaryngol. 2012 Jul;269(7):1857-63
pubmed: 22237760
Clin Neurophysiol. 2013 Jun;124(6):1232-6
pubmed: 23333609
J Am Acad Audiol. 2007 Oct;18(9):725-38
pubmed: 18354882
Otol Neurotol. 2010 Aug;31(6):959-63
pubmed: 20601917
J Physiol. 2012 Jul 1;590(13):3091-101
pubmed: 22526888
J Vestib Res. 2020;30(3):153-158
pubmed: 32623412
J Vestib Res. 2007;17(2-3):89-92
pubmed: 18413901
Pract Otorhinolaryngol (Basel). 1962;24:65-93
pubmed: 14452374
Audiol Neurootol. 2015;20 Suppl 1:38-43
pubmed: 25997394
Clin Neurophysiol. 2017 Feb;128(2):312-322
pubmed: 28042997
J Laryngol Otol. 2011 Apr;125(4):343-7
pubmed: 20955634
Int J Audiol. 2013 Jun;52(6):419-23
pubmed: 23448103
Hear Res. 2016 Jan;331:131-43
pubmed: 26626360
J Vestib Res. 2009;19(1-2):33-40
pubmed: 19893195
Audiol Neurootol. 2014;19(4):239-47
pubmed: 24993062
Clin Neurophysiol. 2010 Jan;121(1):85-9
pubmed: 19892592
Clin Neurophysiol. 2014 Apr;125(4):658-666
pubmed: 24513390
Auris Nasus Larynx. 2016 Aug;43(4):367-76
pubmed: 26791591
Clin Neurophysiol. 2013 Oct;124(10):2066-8
pubmed: 23757380
Ear Hear. 2017 Mar/Apr;38(2):205-211
pubmed: 27787395
Int J Audiol. 2019 Mar;58(3):174-179
pubmed: 30845861
Int J Pediatr Otorhinolaryngol. 2013 Sep;77(9):1555-60
pubmed: 23915488
Ear Hear. 2013 Nov-Dec;34(6):799-805
pubmed: 23732683
J Acoust Soc Am. 2007 Nov;122(5):2772-85
pubmed: 18189568
J Am Acad Audiol. 2011 Apr;22(4):222-30
pubmed: 21586257
Clin Neurophysiol. 2001 Nov;112(11):1971-9
pubmed: 11682335
Ear Hear. 2005 Dec;26(6):559-76
pubmed: 16377993
Clin Neurophysiol. 2009 Feb;120(2):420-3
pubmed: 19097934
Clin Neurophysiol. 2008 Sep;119(9):2135-47
pubmed: 18639490
Int J Audiol. 2015;54(10):745-50
pubmed: 26121565
Clin Neurophysiol. 2016 Aug;127(8):2846-2854
pubmed: 27417061
Audiol Res. 2015 Aug 31;5(2):121
pubmed: 26779326
Ear Hear. 2013 Nov-Dec;34(6):e65-73
pubmed: 23673615
Clin Neurophysiol. 2010 May;121(5):636-51
pubmed: 20080441
Eur Arch Otorhinolaryngol. 2014 Sep;271(9):2401-7
pubmed: 24096809
Clin Neurophysiol. 2015 Nov;126(11):2198-206
pubmed: 25666729
Clin Neurophysiol. 2011 Nov;122(11):2282-9
pubmed: 21550301
Clin Neurophysiol Pract. 2019 Feb 26;4:47-68
pubmed: 30949613
Handb Clin Neurol. 2016;137:133-55
pubmed: 27638068

Auteurs

Quentin Mat (Q)

Department of Otorhinolaryngology, C.H.U. Charleroi, Charleroi, Belgium.
Faculty of Medicine and Pharmacy, University of Mons (UMons), Mons, Belgium.

Jean-Pierre Duterme (JP)

Department of Otorhinolaryngology, C.H.U. Charleroi, Charleroi, Belgium.

Sophie Tainmont (S)

Department of Otorhinolaryngology, C.H.U. Charleroi, Charleroi, Belgium.

Christophe Lelubre (C)

Faculty of Medicine and Pharmacy, University of Mons (UMons), Mons, Belgium.
Department of Internal Medicine, C.H.U. Charleroi, Charleroi, Belgium.

Mario Manto (M)

Faculty of Medicine and Pharmacy, University of Mons (UMons), Mons, Belgium.
Department of Neurology, Médiathèque Jean Jacquy, C.H.U. Charleroi, Charleroi, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH